Dr. Sant P. Chawla on Trabectedin for the Treatment of Mesenchymal Chondrosarcoma
Sant P. Chawla, MD, director, Sarcoma Oncology Center, discusses the potential for trabectedin as treatment of mesenchymal chondrosarcoma.
Sant P. Chawla, MD, director, Sarcoma Oncology Center, discusses the potential for trabectedin as treatment of mesenchymal chondrosarcoma.
Mesenchymal chondrosarcoma is a very rare disease that often has a lot of potential to metastasize, Chawla says.
In this small study of fewer than 20 patients, some patients had previously failed standard chemotherapy and trabectedin did control disease in some of those patients for up to two years.
Moving forward, Chawla says, there will first need to be collaboration between institutions and pharmaceutical companies to determine if similar results have been seen before.
T-DXd Combinations Effective in HER2+ Gastric and GEJ Cancer
September 14th 2024Findings from the DESTINY-Gastric03 study support the further exploration of the antibody-drug conjugate trastuzumab deruxtecan for the first-line treatment of patients with advanced HER2+ gastric, esophageal, and GEJ cancers.
Read More
